FFS according to the bcl-2-breakpoint site (mcr, MBR, and germline) in three subsets of patients with different risks: (A) patients with normal serum LDH and β2M (no significant difference among breakpoints), (B) patients with high LDH or β2M (P = .02), and (C) patients with high LDH and β2M (P = .03).